AbCellera: $1.2B valuation, IPO Readiness 60, Public. Antibody discovery platform using AI and microfluidics to rapidly identify therapeutic antibodies at scale. Track live on The IPO Stack.
Antibody discovery platform using AI and microfluidics to rapidly identify therapeutic antibodies at scale.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track AbCellera IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
AbCellera is already a public company.
AbCellera is valued at $1.2B as of the most recent funding round. This valuation is based on its most recent private funding round tracked by TechStackIPO.
AbCellera is already a public company. You can invest by purchasing shares on public stock exchanges.
AbCellera scores 60/100 (Grade: C) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
AbCellera has raised $105M in total venture capital and private equity funding, with backing from Public markets, OrbiMed, Versant Ventures.
AbCellera's notable investors include Public markets, OrbiMed, Versant Ventures, CIHR. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
AbCellera is a Biotechnology company. Antibody discovery platform using AI and microfluidics to rapidly identify therapeutic antibodies at scale.